← Back
Abbvie
ABBV · listed on the New York Stock Exchange · worth $466.55 billion
$286.74
+0.39% on Oct 26
No insider bought Abbvie stock in the last year. They sold it 5 times, $17.7 million in all. Six members of Congress reported trading Abbvie in the last year.
Red dot = an insider soldA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
1.8B shares
100% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, two insiders sold Abbvie stock and none bought. None of the 5 sales is marked on its filing as planned in advance; all by company executives. The biggest seller was Perry C. Siatis, EVP, GC AND SECRETARY.
Planned sales
Form 144 notices filed for Abbvie in recent months, beside the Form 4 sales reported after each. A notice says a person intends to sell; it is not a sale.
Executive Nicholas Donoghoe filed to sell 32,710 shares on 14 Aug; sold 32,710 by 14 AugNotice on SEC.gov
US Congress
Members of Congress who reported trading Abbvie in the last year. They have up to 45 days to report, so the newest trades show up late.
MemberTradeAmountWhose accountTradedReported
All reports
Every insider trade and SEC report we hold for Abbvie.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Aug 18SoldNicholas DonoghoeAug 18 · Traded Aug 14 · EVP, CHIEF BUS/STRAT OFFICER32,710 @ $250.00$8.18M
3 more with Pro →Analysts, earnings and news
Analysts' price target
$278.61 average
28 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
3 of 4 quarters above
Q2 '26$3.65 a share+$0.04
Q1 '26$2.65 a share−$0.02
Q4 '25$2.71 a share+$0.06
Q3 '25$1.86 a share+$0.08